Literature DB >> 8916788

Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease.

J Morgan1, J C Dias, E D Gontijo, L Bahia-Oliveira, R Correa-Oliveira, D G Colley, M R Powell.   

Abstract

Chagas' disease results from infection with the protozoan hemoflagellate Trypanosoma cruzi. Patients in the chronic phase of infection can be categorized into four groups based on the presence of cardiac abnormalities (CARD), gastrointestinal involvement (DIGEST), a combination of both presentations (BOTH), or indeterminate (IND) if Chagas' related pathology is not apparent. Previous studies have indicated that parasite-specific antibody production is important in both resistance to and pathogenesis of disease. The anti-T. cruzi epimastigote stage antibody isotype profiles in the sera of Brazilian patients from each clinical category, as well as from uninfected individuals (UNINF) from the same endemic area were analyzed. Anti-epimastigote immunoglobulin G (IgG)1 and IgG3 levels were strikingly high with titers > or = 1:100,000. Sera from patients in the CARD group had higher levels of IgM than either UNINF or IND individuals, which is consistent with the theory that autoimmunity may contribute to chagasic cardiomyopathy. The IgA levels were higher in sera from patients with gastrointestinal involvement when compared with individuals from any of the other clinical categories as well as from uninfected controls. Interestingly, patients with both digestive and cardiac involvement did not express high serum levels of IgA. However, like patients with cardiac involvement alone, persons with both clinical manifestations produced elevated levels of IgG2 compared with the IND or UNINF groups. These data suggest the presence of complex immunoregulatory processes, most likely related to differential cytokine involvement, which can influence the expression of antibody isotypes and possibly the course of disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916788     DOI: 10.4269/ajtmh.1996.55.355

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.

Authors:  F D Cordeiro; O A Martins-Filho; M O Da Costa Rocha; S J Adad; R Corrêa-Oliveira; A J Romanha
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

2.  Chagas' disease: IgG isotypes against cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens of Trypanosoma cruzi in chronic Chagasic patients.

Authors:  A F A Verçosa; V M B Lorena; C L Carvalho; M F A D Melo; M G A Cavalcanti; E D Silva; A G P Ferreira; V R A Pereira; W V Souza; Y M Gomes
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.

Authors:  Niamh Murphy; M Victoria Cardinal; Tapan Bhattacharyya; Gustavo F Enriquez; Natalia P Macchiaverna; Alejandra Alvedro; Héctor Freilij; Pablo Martinez de Salazar; Israel Molina; Pascal Mertens; Quentin Gilleman; Ricardo E Gürtler; Michael A Miles
Journal:  Parasit Vectors       Date:  2021-10-20       Impact factor: 3.876

4.  Characterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients.

Authors:  Ivonne D Flechas; Adriana Cuellar; Zulma M Cucunubá; Fernando Rosas; Víctor Velasco; Mario Steindel; María del Carmen Thomas; Manuel Carlos López; John Mario González; Concepción Judith Puerta
Journal:  BMC Infect Dis       Date:  2009-11-25       Impact factor: 3.090

5.  IgG Subclass Analysis in Patients with Chagas Disease 4 Years After Benznidazole Treatment.

Authors:  Maurício Llaguno; Marcos Vinícius da Silva; Fernanda Rodrigues Helmo; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Acta Parasitol       Date:  2021-06-11       Impact factor: 1.440

6.  Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies.

Authors:  Elke S Bergmann-Leitner; Ryan M Mease; Elizabeth H Duncan; Farhat Khan; John Waitumbi; Evelina Angov
Journal:  Malar J       Date:  2008-07-14       Impact factor: 2.979

7.  Different serological cross-reactivity of Trypanosoma rangeli forms in Trypanosoma cruzi-infected patients sera.

Authors:  Milene H de Moraes; Alessandra A Guarneri; Fabiana P Girardi; Juliana B Rodrigues; Iriane Eger; Kevin M Tyler; Mário Steindel; Edmundo C Grisard
Journal:  Parasit Vectors       Date:  2008-07-08       Impact factor: 3.876

8.  Evolution of anti-Trypanosoma cruzi antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity.

Authors:  Ingebourg Georg; Alejandro Marcel Hasslocher-Moreno; Sergio Salles Xavier; Marcelo Teixeira de Holanda; Eric Henrique Roma; Maria da Gloria Bonecini-Almeida
Journal:  PLoS Negl Trop Dis       Date:  2017-07-19

Review 9.  DNA Double-Strand Breaks: A Double-Edged Sword for Trypanosomatids.

Authors:  Marcelo Santos da Silva
Journal:  Front Cell Dev Biol       Date:  2021-04-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.